Oncology Building a Phase I oncology centre The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
R&D Universities and pharma companies need each other to create ... Academics and pharma executives seemingly live in very different worlds.
News Enhertu OK ends 10-year EU gap in frontline breast cancer Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
